In vitro dermal and transdermal delivery of doxycycline from ethanol/migliol 840 vehicles

International Journal of Pharmaceutics

Volumn 190, Issue 2, 1999, Pages 155-164

  Perkins, Nia C ^a   Heard, Charles M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Acne vulgaris; Dermal delivery; Doxycycline; Lyme disease; Malaria; Migliol 840; Reiter syndrome; Transdermal delivery

Indexed keywords

ALCOHOL; DECANOIC ACID DERIVATIVE; DOXYCYCLINE; OCTANOIC ACID DERIVATIVE; PROPANEDIOL DERIVATIVE;

ARTICLE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG INDICATION; DRUG PENETRATION; ESOPHAGUS ULCER; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STRATUM CORNEUM; TOPICAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; AGED; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGLYCERIDES; DOXYCYCLINE; EPIDERMIS; ETHANOL; FEMALE; HUMANS; MALE; MIDDLE AGED; SKIN ABSORPTION; SOLVENTS; VEHICLES;

EID: 0032711736     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00240-9     Document Type: Article

References (27)

1. Abrams K., Harvell J., Shriner D., Wertz P., Maibach H., Rehfeld S. Effect of organic solvents on in vitro human skin water barrier function. Soc. Inv. Dermatol. 101(4):1993;609-613.
2. Barry B. Dermatological Formulations: Percutaneous Absorption. 1983;Marcel Dekker, Inc, NY.
3. Bogardus J., Blackwood R. Solubility of doxycycline in aqueous solution. J. Pharm. Sci. 68(2):1979;188-194.
4. Bommannan D., Potts R., Guy R. Examination of the effect of ethanol on human stratum corneum in vivo using infrared spectroscopy. J. Controlled Release. 16:1991;299-304.
5. Elias P., Friend D. The permeability barrier in mammalian epidermis. J. Cell Biol. 65:1975;180-191.
6. Fedors R. A method for estimating both the solubility parameters and molar volumes of liquids. Polym. Eng. Sci. 14(2):1974;147-154.
7. Finch R. Tetracyclines. O'Grady F., Lambert H., Finch R., Greenwood D. Antibiotic and Chemotherapy: Anti-infective Agents and their Use in Therapy. seventh ed. 1996;469-477 Churchill Livingston, London.
8. Foster J., Sylvia L. Doxycycline-induced eosophageal ulceration. Ann. Pharmacother. 28:1994;1185-1187.
9. Hasiguchi T., Kodama A., Ryu A., Otagiri M. Retention capacity of topical imidazole antifungal agents in the skin. Int. J. Pharm. 161:1998;195-204.
10. Kotecka B., Edstein M., Rieckmann K. Chloroquine bioassay of plasma specimens obtained from soldiers on chloroquine plus doxycycline for malaria prophylaxis. Int. J. Parasitol. 26(11):1996;1325-1329.
11. Langston K., Brain K.R., Heard C.M. The permeation of doxycycline across human skin in vitro. Brain K.R., Walters K. Perspectives in Percutaneous Penetration. 6a:1998;91 STS Publishing, Cardiff.
12. Layton A., Cunliffe W. Phototoxic eruptions due to doxycycline: a dose-related phenomenon. Clin. Exp. Dermatol. 18:1993;425-427.
13. Liron Z., Cohen S. Percutaneous absorption of alkanoic acids 1: a study of operational conditions. J. Pharm. Sci. 73:1984;534-537.
14. Mayorga P., Puisieux F., Couarraze G. Formulation study of a transdermal delivery system of primaquine. Int. J. Pharm. 132:1996;71-79.
15. Mehta D. British National Formulary, Number 34. 1998;British Medical Association and The Royal Pharmaceutical Society of Great Britain, London.
16. Morris A., Kee W.J., Brain K.R., Heard C.M., Watkinson A.C. Vehicle effects in the permeation of primaquine across human skin in vitro. Brain K.R., James V.J., Walters K. Perspectives in Percutaneous Penetration. 5b:1998;180-182 STS Publishing, Cardiff.
17. Naidong W., Hua S., Roets E., Busson R., Hoogmartens J. Investigation of keto-enol tautomerisation and ionisation of doxycycline in aqueous solutions. Int. J. Pharm. 96:1981;13-21.
18. Ohrt C., Richie T.L., Widjaja H., Shanks D., Fitriadi J., Fryauff D.J. et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers - a randomized, double-blind, placebo- controlled trial. Ann. Int. Med. 126(12):1997;963-972.
19. Rothe M., Kerdel F. Reiter Syndrome. Int. J. Dermatol. 30:1991;173-180.
20. Schaefer H., Redelmeier T. Skin Barrier-principles of Percutaneous Absorption. 1996;Karger, London.
21. Schreiner A., Digranes A. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. Chemotherapy. 31:1985;261-265.
22. Skelly J., Shah V., Maibach H., Guy R., Wester C., Flynn G. et al. FDA and AAPS report of the workshop on principles and practices of in vitro percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm. Res. 4(3):1987;265-267.
23. Steere A. Lyme disease. N. Engl. J. Med. 321(9):1989;586-596.
24. Tanaka N., Kawada A., Ohnishi Y., Hiruma M., Tajima S., Akiyama M. et al. Photosensitivity due to doxycycline hydrochloride with an unusual flare. Contact Dermat. 37:1997;93-94.
25. Touitou E., Meidan V., Horwitz E. Methods for quantitative determination of drug localised in the skin. J. Controlled Release. 56:1998;7-21.
26. Van Mierlo P. Erythemas chronicum migrans: an electron-microscopic study. Dermatology. 186(4):1993;306-310.
27. Wechsler H., Kirk J., Slone J. Acne treated with a topical tetracycline preparation: results of a 1-year multi-group study. Int. J. Dermatol. 17:1978;237-242.